Swedbank AB Reduces Holdings in Hologic, Inc. $HOLX

Key Points

• Swedbank AB has reduced its stake in Hologic, Inc. by 20.7%, selling 263,009 shares and now holding around 1,008,793 shares valued at approximately $62.3 million.
• Despite Swedbank's sell-off, other institutional investors have increased their positions in Hologic, with significant stake increases from firms like Inspire Investing LLC and Empowered Funds LLC.
• Hologic's recent earnings report exceeded expectations, with a net revenue of $1.02 billion and earnings per share of $1.08, prompting upgrades from several analysts regarding their price targets.

Swedbank AB reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,008,793 shares of the medical equipment provider's stock after selling 263,009 shares during the quarter. Swedbank AB owned about 0.45% of Hologic worth $62,313,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Victory Capital Management Inc. boosted its position in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Invesco Ltd. boosted its position in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after acquiring an additional 69,878 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Hologic by 0.8% during the 1st quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after acquiring an additional 29,133 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Hologic by 8.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after acquiring an additional 213,366 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 1.0%

Shares of NASDAQ:HOLX traded down $0.65 on Monday, hitting $63.80. 1,276,134 shares of the company's stock were exchanged, compared to its average volume of 1,330,759. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The stock has a market capitalization of $14.19 billion, a price-to-earnings ratio of 26.47, a price-to-earnings-growth ratio of 2.34 and a beta of 0.57. The business's 50 day simple moving average is $66.42 and its two-hundred day simple moving average is $62.64. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the company earned $1.06 earnings per share. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on HOLX shares. Morgan Stanley increased their target price on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and raised their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. UBS Group raised their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. Finally, Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and an average price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.